Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Ocugen	Atara Biotherapeutics	Mesoblast	Cortexyme	Curis
Symbol	NASDAQ:OCGN	NASDAQ:ATRA	NASDAQ:MESO	NASDAQ:CRTX	NASDAQ:CRIS
Price Information
Current Price	$9.76	$13.96	$6.73	$36.52	$9.69
52 Week Range	Buy	Buy	Hold	Hold	Buy
MarketRank™
Overall Score	1.0	1.4	1.4	1.6	1.3
Analysis Score	1.3	3.4	3.2	3.1	3.5
Community Score	3.3	2.8	3.1	2.6	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.0	2.5	0.0
Earnings & Valuation Score	0.6	0.6	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Hold	Hold	Buy
Consensus Price Target	$8.38	$35.88	$14.55	$50.00	$14.60
% Upside from Price Target	-14.19% downside	156.98% upside	116.20% upside	36.91% upside	50.67% upside
Trade Information
Market Cap	$1.91 billion	$1.11 billion	$921.15 million	$990.01 million	$890.48 million
Beta	3.56	2.65	3.71	0.95	3.29
Average Volume	74,581,320	923,315	547,550	281,429	1,964,250
Sales & Book Value
Annual Revenue	N/A	N/A	$32.16 million	N/A	$10 million
Price / Sales	N/A	N/A	27.15	N/A	88.68
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.21 per share	$5.37 per share	$4.70 per share	$4.30 per share	($1.02) per share
Price / Book	N/A	N/A	1.43	N/A	-9.50
Profitability
Net Income	$-20,240,000.00	$-290,980,000.00	$-77,940,000.00	$-36,980,000.00	$-32,140,000.00
EPS	($1.48)	($5.67)	($0.74)	($1.94)	($0.86)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	-591.00%	N/A	-279.33%
Return on Equity (ROE)	-47.72%	-94.86%	-18.69%	-37.78%	N/A
Return on Assets (ROA)	-30.78%	-82.17%	-13.85%	-35.24%	-81.32%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.13%	N/A	0.10%	N/A	N/A
Current Ratio	4.78%	9.41%	1.32%	8.71%	3.10%
Quick Ratio	4.78%	9.41%	1.32%	8.71%	3.10%
Ownership Information
Institutional Ownership Percentage	8.53%	N/A	2.80%	55.48%	34.66%
Insider Ownership Percentage	3.54%	4.30%	18.80%	19.80%	7.34%
Miscellaneous
Employees	15	480	102	37	28
Shares Outstanding	188.17 million	84.08 million	129.74 million	29.59 million	91.52 million
Next Earnings Date	8/13/2021 (Estimated)	8/4/2021 (Estimated)	5/26/2021 (Estimated)	8/16/2021 (Estimated)	5/12/2021 (Confirmed)
Optionable	Not Optionable	Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	Is Curis, Inc. (CRIS) Stock at the Top of the Biotechnology Industry? - InvestorsObserver investorsobserver.com - May 11 at 10:54 AM
	Chemocentryx’s future in doubt as avacopan foundation crumbles - Vantage evaluate.com - May 10 at 2:33 PM
	Curis, Inc. to Post FY2022 Earnings of ($0.19) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRIS) americanbankingnews.com - May 7 at 9:24 AM
	Curis (CRIS) to Release Earnings on Wednesday americanbankingnews.com - May 6 at 12:46 PM
	Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology - StreetInsider.com streetinsider.com - May 5 at 6:23 PM
	Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021 - Yahoo Finance finance.yahoo.com - May 5 at 1:23 PM
	Curis to Release First Quarter 2021 Financial Results and Hold Conference Call on May 12, 2021 finance.yahoo.com - May 5 at 1:23 PM
	Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance finance.yahoo.com - May 4 at 6:23 PM
	Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know finance.yahoo.com - May 4 at 6:23 PM
	Zacks: Brokerages Anticipate Curis, Inc. (NASDAQ:CRIS) Will Announce Earnings of -$0.09 Per Share americanbankingnews.com - May 4 at 2:26 PM
	Global Hodgkin Lymphoma Treatment Market by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), By Application (Hospital, Clinic, Research Center) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028 - Good News Gum goodnewsgum.com - May 4 at 1:23 PM
	Sneak peek at McDonald’s Gospelfest 2021 - WPIX 11 New York pix11.com - May 4 at 1:23 PM
	Alliance Wealth Management Gro - GuruFocus.com gurufocus.com - May 4 at 1:23 PM
	Alliance Wealth Management Group Buys Invesco Fundamental High Yield Corporate Bond ETF, Curis ... gurufocus.com - May 4 at 11:16 AM
	Curis Stock Shows Every Sign Of Being Significantly Overvalued - Yahoo Finance finance.yahoo.com - May 3 at 10:21 PM
	Hodgkin Lymphoma Treatment Market to Witness Huge Growth by 2026 \| Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis - Clark County Blog clarkcountyblog.com - May 3 at 12:21 PM
	Short Interest in Curis, Inc. (NASDAQ:CRIS) Decreases By 27.2% americanbankingnews.com - May 2 at 11:54 AM
	Histone Deacetylase 1 Market Research with COVID-19 \| 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County Blog clarkcountyblog.com - April 30 at 8:35 PM
	Histone Deacetylase 2 Market Size Prognosticated to Perceive a Thriving Growth by 2026 interpreted by a new report \| 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County Blog clarkcountyblog.com - April 29 at 11:45 PM
	Hodgkin Lymphoma Treatment Market Booming Segments; Investors Seeking Growth \| Curis, Incyte, Cell Medica – Jumbo News - Jumbo News jumbonews.co.uk - April 28 at 2:38 PM
	Track Magnets Market Size, Status, Global Demands and Top Manufacturers 2021 \| 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County Blog clarkcountyblog.com - April 28 at 2:38 PM
	Apremilast Reagent Market to Witness Growth Acceleration by Top Key Players – 4SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc. - Clark County Blog clarkcountyblog.com - April 28 at 2:38 PM
	These numbers prove just how vibrant the Curis, Inc. (NASDAQ:CRIS) stock has been stocksregister.com - April 28 at 9:38 AM
	Curis, Inc. (NASDAQ:CRIS): Stock Forecast For 2021 Still Looks Hot With A 1.7% Increase marketingsentinel.com - April 28 at 12:02 AM
	Hodgkin Lymphoma Treatment Market 2021 Size, Share Industry Trends, Growth, Development Status, Future Plans Analysis by 2027\| Key Companies Analysis- Cell Medica Limited, Cellular Biomedicine Group, Inc., Constellation Pharmaceuticals, Inc., Curis, Inc., Faron Pharmaceuticals Oy, etc. - Clark County Blog clarkcountyblog.com - April 27 at 8:58 AM

Date	Company	Brokerage	Action
5/10/2021	Ocugen	Chardan Capital	Lower Price Target
5/7/2021	Ocugen	Cantor Fitzgerald	Downgrade
3/4/2021	Ocugen	Roth Capital	Boost Price Target
2/4/2021	Ocugen	HC Wainwright	Upgrade
3/2/2021	Atara Biotherapeutics	William Blair	Reiterated Rating
3/2/2021	Atara Biotherapeutics	Citigroup	Upgrade
12/9/2020	Atara Biotherapeutics	Smith Barney Citigroup	Downgrade
12/9/2020	Atara Biotherapeutics	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade
12/7/2020	Atara Biotherapeutics	Stifel Nicolaus	Boost Price Target
11/23/2020	Atara Biotherapeutics	Mizuho	Boost Price Target
9/14/2020	Atara Biotherapeutics	Canaccord Genuity	Boost Price Target
6/30/2020	Atara Biotherapeutics	Evercore ISI	Initiated Coverage
5/12/2020	Atara Biotherapeutics	JPMorgan Chase & Co.	Boost Price Target
12/10/2019	Atara Biotherapeutics	Cowen	Reiterated Rating
4/13/2021	Mesoblast	Maxim Group	Upgrade
1/19/2021	Mesoblast	Jefferies Financial Group	Downgrade
10/22/2020	Mesoblast	Royal Bank of Canada	Initiated Coverage
5/28/2020	Mesoblast	LADENBURG THALM/SH SH	Boost Price Target
12/19/2019	Mesoblast	Dawson James	Initiated Coverage
9/10/2019	Mesoblast	Oppenheimer	Set Price Target
12/7/2020	Cortexyme	Bank of America	Upgrade
9/24/2020	Cortexyme	Lifesci Capital	Reiterated Rating
6/3/2019	Cortexyme	Credit Suisse Group	Initiated Coverage
6/3/2019	Cortexyme	JMP Securities	Initiated Coverage
3/30/2021	Curis	B. Riley	Initiated Coverage
3/17/2021	Curis	Jonestrading	Boost Price Target
7/29/2020	Curis	Laidlaw	Initiated Coverage
8/3/2018	Curis	SunTrust Banks	Lower Price Target

(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources